Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan
Дата публикации: 10-07-2026 07:07:00

New indication concerns monotherapy for patients with advanced TNBC who have not received prior systemic treatment for metastatic disease and who are not candidates for PD-(L)1 inhibitors

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
2EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan0526-06-2026
3EMA Recommends Extension of Therapeutic Indications for Encorafenib0503-07-2026
4FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC5724-06-2026
5New targeted therapy shows promising early results in advanced pancreatic cancer2705-07-2026
6New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer5702-07-2026
7FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer5508-07-2026
8Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions0523-06-2026
9أدوية جديدة تحل محل العلاج الكيميائي لسرطان الثدي العدواني5725-06-2026
10Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma0502-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.esmo.org.